vai al contenuto della pagina vai al menu di navigazione

PRISM - Providing quantitative biological measures to facilitate the discovery and development of new treatments for social and cognitive deficits in Alzheimer’s disease, schizophrenia and depression

3 - Good health and well-being; Research Projects; 2016; 2017; 2018; 2019

The overall objective of this project is to develop a quantitative biological approach to the understanding and classification of neuropsychiatric diseases to accelerate the discovery and development of better treatments for patients. The concept of our proposal is to define a set of quantifiable biological parameters for social withdrawal and cognitive deficits to cluster and differentiate schizophrenia (SZ), Alzheimer’s disease (AD), and to a lesser degree, patients with major depressive disorder (MD). In phase I of the project (years 1-3), the following specific objectives will be addressed:
1. Proof-of-concept (PoC) analyses to cluster and differentiate SZ and AD patients on the basis of quantitative biological parameters.
2. Explore dimensional relationships between pathology (e.g., cognitive deficits) and social withdrawal.
3. Develop deeper understanding of the quantitative biology of social withdrawal using clinical data from SZ, AD and MD patients and by establishing a network of pre-clinical research sites able to perform high quality back-translation studies.
4. Develop the regulatory path for social withdrawal across disorders.

Follow us: